Angiogenesis in the eye underlies the major causes of blindness in both developed and developing nations: exudative age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), neovascular glaucoma, corneal neovascularization (trachoma), and pterygium. Presently approved anti-angiogenic therapies for ophthalmic conditions are biologic agents that inhibit VEGF. There are currently two approved antiangiogenic therapies for ophthalmic diseases: an anti-VEGF aptamer (pegaptanib, Macugen); and a Fab fragment of a monoclonal antibody directed against VEGF-A (ranibizumab, Lucentis).
For a list of anti-angiogenic therapies approved for ophthalmic diseases please check our Treatments page.